Product Information
CLINDAMYCIN HCL 300 MG CAPSULE is a generic product labeled by Major Pharmaceuticals, priced at $0.1746 per EA under NDC 00904719461. Its NADAC has been published 233 times since Apr 20, 2022.
FDA first approved this application on Aug 26, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904719461
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLINDAMYCIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA065442FDA Approved
8/26/2009
TE Code
AB
On Market Since
8/26/2009
Pharmacological Classes
Price Statistics
The NADAC for CLINDAMYCIN HCL 300 MG CAPSULE has been published 233 times since Apr 20, 2022, and over the history we have for it it has declined 33.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1746 per EA |
|---|---|
| All-time high | $0.2735 (Jun 15, 2022) |
| All-time low | $0.1674 (Nov 20, 2024) |
| 52-week high | $0.1849 |
| 52-week low | $0.1680 |
| Median price | $0.2085 |
| Average price | $0.2147 |
| Largest weekly change | +33.6% (Aug 21, 2024) |
| Weeks tracked | 233 |
| Tracking since | Apr 20, 2022 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clindamycin Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lincosamide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLINDAMYCIN HCL 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CLINDAMYCIN HCL 300 MG CAPSULE, manufactured by Major Pharmaceuticals, is $0.1746 per EA (NDC 00904719461), effective Sep 30, 2026.
How has the price of CLINDAMYCIN HCL 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CLINDAMYCIN HCL 300 MG CAPSULE has declined 33.4%. It has been tracked across 233 weekly CMS publications since Apr 20, 2022.
What are the highest and lowest recorded NADAC prices for CLINDAMYCIN HCL 300 MG CAPSULE?
Since Apr 20, 2022, the NADAC for CLINDAMYCIN HCL 300 MG CAPSULE has ranged from a low of $0.1674 (Nov 20, 2024) to a high of $0.2735 (Jun 15, 2022), with a median of $0.2085 per EA.
Are there cheaper alternatives to CLINDAMYCIN HCL 300 MG CAPSULE?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CLINDAMYCIN HCL 300 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures CLINDAMYCIN HCL 300 MG CAPSULE?
CLINDAMYCIN HCL 300 MG CAPSULE (NDC 00904719461) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.